Satt Sud-Est has licensed Yukin Therapeutics to commercialise patents originating from several French institutions on the back of inventions from regional research hub Canceropôle Provence-Alpes-Côte d'Azur.

French regional tech transfer office Satt Sud-Est today granted an exclusive licence to France-based pharmaceutical development startup Yukin Therapeutics covering immunotherapy patents jointly owned by multiple French institutions.
The patents cover intellectual property jointly owned by Nice Sophia Antipolis University, Inserm, the French National Center for Scientific Research and Nice University Hospital, building on inventions originating from regional cancer research hub Canceropôle Provence-Alpes-Côte d’Azur (Canceropôle PACA).
Yukin Therapeutics will advance immunotherapeutic candidates for cancer that induce an anti-tumour…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?